Search Results

TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition

• Authors : Lazarevic, Vladimir; Lilljebjörn, Henrik; Olsson-Arvidsson, Linda ...

Subjects: Medical and Health Sciences; Basic Medicine; Medical Genetics and Genomics (including Gene Therapy)

• Source: Genes Chromosomes and Cancer. 63(8):1-8

Record details

Polymorphism of Janus Kinase 2 and Telomerase Reverse Transcriptase Genes in Iraqi Patients with Myeloproliferative Neoplasm.

• Authors : Nasif, Zaizafoon N.¹ ; Muftin, Najlaa Qassim¹; Hameed, Aseel M.²

• Source: Iraqi Journal of Science. 2025, Vol. 66 Issue 3, p1062-1070. 9p.

Record details

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

• Source: Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic

Record details

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

• Source: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on

Record details

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

• Source: A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential

Record details

CRISPR/Cas9-Based Modeling of JAK2 V617F Mutation in K562 Cells Reveals Enhanced Proliferation and Sensitivity to Therapeutic Agents.

• Authors : Nilsri, Nungruthai^1,2 (AUTHOR); Mekchaaum, Rujira^1,2 (AUTHOR); Kalasin, Supaporn¹ (AUTHOR)

Subjects: *Genetic mutation; *Gene expression; *Polycythemia vera

• Source: International Journal of Molecular Sciences. May2025, Vol. 26 Issue 10, p4600. 13p.

Record details

High-throughput inhibitor screening and molecular dynamics simulation studies against Human JAK2.

• Authors : Zahed, Rawabi^1,2 ; Abuzenadah, Adel M.^2,3; Shakil, Shazi^3,4,5

• Source: Tropical Journal of Pharmaceutical Research. May2025, Vol. 24 Issue 5, p599-605. 7p.

Record details

Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis.

• Authors : Wang, Fuping^1,2 (AUTHOR) ; Chen, Longxin³ (AUTHOR); Zhang, Limeng³ (AUTHOR)

Subjects: *ACUTE myeloid leukemia; *MEDICAL sciences; *EXTRAMEDULLARY hematopoiesis

• Source: Egyptian Journal of Medical Human Genetics. 12/16/2024, Vol. 25 Issue 1, p1-10. 10p.

Record details

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

• Authors : Naumann, Nicole¹ (AUTHOR); Dangelo, Vito¹ (AUTHOR); Lübke, Johannes¹ (AUTHOR)

• Source: Scientific Reports. 7/18/2025, Vol. 15 Issue 1, p1-12. 12p.

Record details

ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA Open Access.

• Authors : Soderholm, Adrian^1,2,3 (AUTHOR); Vunjak, Milica^1,2,3 (AUTHOR); de Almeida, Melanie^3,4 (AUTHOR)

Subjects: *Interferon gamma; *Janus kinases; *Genetic transcription regulation

• Source: Nucleic Acids Research. 7/8/2025, Vol. 53 Issue 12, p1-24. 24p.

Record details